IRVINE, Calif.–(BUSINESS WIRE)–Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced survey results of 137 patients previously implanted with the Medtronic InterStim II™ that are now being treated with the Axonics r-SNM System.
In the survey, Axonics asked patients about Axonics SNM therapy and to make comparisons to their prior experience with InterStim II. Key findings of the survey include:
Raymond W. Cohen, Axonics CEO, said, “We specifically surveyed these particular patients because they have a direct basis of comparison and can provide unbiased feedback on both devices. The fact that 92% of patients that have been treated with both systems would choose Axonics over InterStim is compelling and underscores that patients want an implant that is long-lived, efficacious and easy to interface with. It is also clear that physicians have great influence over decisions patients make. This informs us that Axonics has to continue to make physicians aware that there are significant and distinct advantages of our r-SNM System over InterStim II which, as of today, is still being implanted despite employing voltage-controlled technology that was originally engineered over 20 years ago.”
Cohen continued, “Delivering a superior experience to patients has been the key focus of our product development initiatives since Axonics’ founding. We remain confident that our keen focus on innovation, enhancing the patient experience, and increasing awareness of SNM therapy will drive significant market expansion in the years ahead.”
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. Axonics SNM therapy, which has been clinically proven to reduce symptoms and restore pelvic floor function, is now being offered at hundreds of medical centers across the U.S. and in dozens of select hospitals in Western Europe. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. The Axonics System is the first long-lived rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. For more information, visit www.axonics.com.
Contacts
Neil Bhalodkar
949-336-5293
IR@axonics.com
OTTAWA, ON, June 17, 2024 /CNW/ - Today, the Honourable François-Philippe Champagne, Minister of Innovation,…
Newly Embedded Prior Authorizations in the Parachute Platform Reduce Costs and Streamlines Administration for Health Plans,…
- Company invited to speak during three symposia on the impact of quality improvement, the…
REDDING, Calif., June 17, 2024 /PRNewswire/ -- According to a new market research report, 'Dental 3D…
TEL AVIV, Israel, June 17, 2024 /PRNewswire/ -- Briya, a leading medical data retrieval network,…
Potential partners are invited to explore collaboration opportunities with VUNO Med®-DeepBrain®, a highly accurate AI…